Efficacy of Fetal Stem Cell Transplantation in Autism Spectrum Disorders: An Open-Labeled Pilot Study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Autism spectrum disorders (ASDs) are heterogeneous complex neurodevelopmental pathologies defined by behavioral symptoms, but which have well-characterized genetic, immunological, and physiological comorbidities. Despite extensive research efforts, there are presently no agreed upon therapeutic approaches for either the core behaviors or the associated comorbidities. In particular, the known autoimmune disorders associated with autism are appealing targets for potential stem cell therapeutics. Of the various stem cell populations, fetal stem cells (FSCs) offer the potent immunoregulatory functions found in primordial mesenchymal stem cells, while exhibiting rapid expansion capacity and recognized plasticity. These properties enhance their potential for clinical use. Furthermore, FSCs are potent and implantable “biopharmacies” capable of delivering trophic signals to the host, which could influence brain development. This study investigated the safety and efficacy of FSC transplantations in treating children diagnosed with ASDs. Subjects were monitored at pre, and then 6 and 12 months following the transplantations, which consisted of two doses of intravenously and subcutaneously administered FSCs. The Autism Treatment Evaluation Checklist (ATEC) test and Aberrant Behavior Checklist (ABC) scores were performed. Laboratory examinations and clinical assessment of adverse effects were performed in order to evaluate treatment safety. No adverse events of significance were observed in ASD children treated with FSCs, including no transmitted infections or immunological complications. Statistically significant differences ( p < 0.05) were shown on ATEC/ABC scores for the domains of speech, sociability, sensory, and overall health, as well as reductions in the total scores when compared to pretreatment values. We recognize that the use of FSCs remains controversial for the present. The results of this study, however, warrant additional investigations into the mechanisms of cell therapies for ASDs, while prompting the exploration of FSCs as “biopharmacies” capable of manufacturing the full array of cell-signaling chemistry. This manuscript is published as part of the International Association of Neurorestoratology (IANR) special issue of Cell Transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lv, Y.-T., Zhang, Y., Liu, M., Qiuwaxi, J.-N.-T., Ashwood, P., Cho, S. C., Huan, Y., Ge, R.-C., Chen, X.-W., Wang, Z.-J., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-196 · Cited by 174 · cited 1×
“It has already been demonstrated that intravenous injection is a safe and efficacious route for cell therapy in autistic children (14).”
BackgroundAutologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Proof of Concept Study
Sharma, A., Gokulchandran, N., Sane, H., Nagrajan, A., Paranjape, A., Kulkarni, P., Shetty, A., Mishra, P., Kali, M., Biju, H., et al. (2013) · Stem Cells International · doi:10.1155/2013/623875 · Cited by 110 · cited 2×
“Similarly, in a study conducted from the same research group, BMMNCs were able to improve autistic behaviors in 32 autistic patients (21).”
BackgroundResult
Cited by
Inflammation and Neuro-Immune Dysregulations in Autism Spectrum Disorders
Siniscalco, D., Schultz, S., Brigida, A. L., & Antonucci, N. (2018) · Pharmaceuticals · doi:10.3390/ph11020056 · Cited by 293
Self-citationThe Gut-Immune-Brain Axis in Autism Spectrum Disorders; A Focus on Amino Acids
van Sadelhoff, J. H. J., Perez Pardo, P., Wu, J., Garssen, J., van Bergenhenegouwen, J., Hogenkamp, A., Hartog, A., & Kraneveld, A. D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00247 · Cited by 71
Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
Cell Therapies for Autism Spectrum Disorder Based on New Pathophysiology: A Review
Nabetani, M., Mukai, T., & Taguchi, A. (2023) · Cell Transplantation · doi:10.1177/09636897231163217 · Cited by 13
Metadata
- Authors
- Bradstreet, J. J., Sych, N., Antonucci, N., Klunnik, M., Ivankova, O., Matyashchuk, I., Demchuk, M., & Siniscalco, D.
- Venue
- Cell Transplantation
- Publisher
- SAGE Publications
- Published
- 2014-01
- Volume
- 23
- Issue
- 1_suppl
- Pages
- 105-112
- ISSN
- 0963-6897 (ISSN-L)
- 1555-3892
- OpenAlex
- W2070064880
- Cited by
- 68
- References
- 2
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Fetal Stem Cell Transplantation in Autism Spectrum Disorders: An Open-Labeled Pilot Study. https://app.cochat.ai/papers/10.3727/096368914x684916
- The paper
- Bradstreet, J. J., Sych, N., Antonucci, N., Klunnik, M., Ivankova, O., Matyashchuk, I., Demchuk, M., & Siniscalco, D. (2014). Efficacy of Fetal Stem Cell Transplantation in Autism Spectrum Disorders: An Open-Labeled Pilot Study. Cell Transplantation. https://doi.org/10.3727/096368914x684916
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.